Three decades of progress in treating childhood-onset lupus nephritis

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 9, 2011, Pages 2192-2199

  Pereira, Tanya ^a   Abitbol, Carolyn L ^a   Seeherunvong, Wacharee ^a   Katsoufis, Chryso ^a   Chandar, Jayanthi ^a   Freundlich, Michael ^a   Zilleruelo, Gastón ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HISPANIC; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; NEPHROSIS; ONSET AGE; OVERALL SURVIVAL; PRESCHOOL CHILD; PROGNOSIS; PROTEINURIA; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADOLESCENT; AGE OF ONSET; CHILD; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HISPANIC AMERICANS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; RETROSPECTIVE STUDIES;

EID: 80052604190     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00910111     Document Type: Article

References (37)

1. Papadimitraki ED, Isenberg DA: Childhood-and adult-onset lupus: An update of similarities and differences. Expert Rev Clin Immunol 5: 391-403, 2009
2. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314: 614-619, 1986
3. McCune WJ, Fox D: Intravenous cyclophosphamide therapy of severe SLE. Rheum Dis Clin North Am 15: 455-477, 1989
4. Steinberg AD, Steinberg SC: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34: 945-950, 1991
5. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343: 1156-1162, 2000
6. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353: 2219-2228, 2005
7. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D. Aspreva Lupus Management Study Group: Mycophenolate mofetil compared with intravenous cyclophosphamide as induction treatment for lupus nephritis. J Am Soc Nephrol 20: 1103-1112, 2009
8. Paredes A: Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis? Pediatr Nephrol 22: 1077-1082, 2007
9. Niaudet P: Treatment of lupus nephritis in children. Pediatr Nephrol 14: 158-166, 2000
10. Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741-745, 1992
11. Meislin AG, Rothfield N: Systemic lupus erythematosus in childhood. Analysis of 42 cases, with comparative data on 200 adult cases followed concurrently. Pediatrics 42: 37-49, 1968
12. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125: 549-557, 1996
13. Opastirakul S, Chartapisak W: Infection in children with lupus nephritis receiving pulse and oral cyclophosphamide therapy. Pediatr Nephrol 20: 1750-1755, 2005
14. Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS: Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: A meta-analysis and meta-regression. Rheumatology (Oxford) 48: 944-952, 2009
15. Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K: B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52: 3168-3174, 2005
16. Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G: Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 23: 413-419, 2008
17. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M: The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65: 521-530, 2004, erratum in Kidney Int 65: 1132, 2004
18. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A: A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58: 259-263, 1976
19. Ginzler E, Diamond H, Guttadauria M, Kaplan D: Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis. Arthritis Rheum 19: 693-699, 1976
20. Dinant HJ, Decker JL, Klippel JH, Balow JE, Plotz PH, Steinberg AD: Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med 96: 728-736, 1989
21. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39: S1-S266, 2002
22. Abitbol CL, Chandar J, Onder AM, Nwobi O, Montané B, Zilleruelo G: Profiling proteinuria in pediatric patients. Pediatric Nephrol 21: 995-1002, 2006
23. Krieger N: Overcoming the absence of socioeconomic data in medical records: Validation and application of a censusbased methodology. Am J Public Health 82: 703-710, 1992
24. Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K, Nahar N, de La Cuesta C, Hurtado A, Fornoni A, Beltran-Garcia L, Asif A, Young L, Diego J, Zachariah M, Smith-Norwood B: Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 69: 1846-1851, 2006
25. Hiraki LT, Benseler SM, Tyrrell PN, Harvey E, Hebert D, Silverman ED: Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol 36: 2539-2546, 2009
26. Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, Eddy A, Gladman D, Urowitz M, Hebert D, Silverman E: Long-term follow-up of childhood lupus nephritis. J Rheumatol 29: 2635-2642, 2002
27. Uribe AG, McGwin G Jr, Reveille JD, Alarco ́n GS: What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. Nurture) cohort? Where are we heading? Autoimmun Rev 3: 321-329, 2004
28. Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman R, Peterson MG, Kimberly RP: Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 97: 1348-1354, 1996
29. Namjou B, Gray-McGuire C, Sestak AL, Gilkeson GS, Jacob CO, Merrill JT, James JA, Wakeland EK, Li QZ, Langefeld CD, Divers J, Ziegler J, Moser KL, Kelly JA, Kaufman KM, Harley JB: Evaluation of C1q genomic region in minority racial groups of lupus. Genes Immun 10: 517-524, 2009
30. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D: Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971-980, 2004
31. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sánchez-Guerrero J, Wofsy D, Yu X, Solomons N: Influence of race/ethnicity on response to lupus nephritis treatment: The ALMS study. Rheumatology (Oxford) 49: 128-140, 2010
32. Melander C, Sallée M, Trolliet P, Candon S, Belenfant X, Daugas E, Rémy P, Zarrouk V, Pillebout E, Jacquot C, Boffa JJ, Karras A, Masse V, Lesavre P, Elie C, Brocheriou I, Knebelmann B, Noël LH, Fakhouri F: Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 4: 579-587, 2009
33. Beharrie A, Franc-Guimond J, Rodriguez MM, Au J, Zilleruelo G, Abitbol CL: A functional immature model of chronic partial ureteral obstruction. Kidney Int 65: 1155-1161, 2004
34. Askenazi D, Myones B, Kamdar A, Warren R, Perez M, De Guzman M, Minta A, Hicks MJ, Kale A: Outcomes of children with proliferative lupus nephritis: The role of protocol renal biopsy. Pediatr Nephrol 22: 981-986, 2007
35. Lau KK, Jones DP, Hastings MC, Gaber LW, Ault BH: Shortterm outcomes of severe lupus nephritis in a cohort of predominantly African-American children. Pediatr Nephrol 21: 655-662, 2006
36. Lau KK, Jones DP, Ault BH: Prognosis of lupus membranous nephritis in children. Lupus 16: 70, 2007
37. Sule S, Fivush B, Neu A, Furth S: Increased risk of death in pediatric and adult patients with ESRD secondary to lupus. Pediatr Nephrol 26: 93-98, 2011